CN Patent

CN108285439B — 一种碳糖苷类钠葡萄糖转运蛋白体2抑制剂

Assigned to Jiangsu Tasly Diyi Pharmaceutical Co Ltd · Expires 2023-05-02 · 3y expired

What this patent protects

本发明涉及一种碳糖苷类钠葡萄糖转运蛋白体2抑制剂，其制备方法和用途，本发明的碳糖苷类钠葡萄糖转运蛋白体2抑制剂，具有通式(Ⅰ)的结构

USPTO Abstract

本发明涉及一种碳糖苷类钠葡萄糖转运蛋白体2抑制剂，其制备方法和用途，本发明的碳糖苷类钠葡萄糖转运蛋白体2抑制剂，具有通式(Ⅰ)的结构

Drugs covered by this patent

Jardiance (empagliflozin) · Boehringer Ingelheim

Patent Metadata

Patent number: CN108285439B
Jurisdiction: CN
Classification: —
Expires: 2023-05-02
Drug substance claim: No
Drug product claim: No
Assignee: Jiangsu Tasly Diyi Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.